GLP-1 Medications and Hair Shedding: What We Know So Far

A few months into a weight-loss program, you may notice more hair in the shower or a ponytail that feels thinner. If you are taking a GLP-1 medication, it is reasonable to wonder whether the two are connected.

The short answer is that hair loss has been reported more often in people taking some GLP-1 and dual GIP/GLP-1 medications. The harder question is why. Rapid weight change, lower calorie or nutrient intake, the physical stress of a major metabolic shift, and a direct medication effect have all been discussed. Current research does not prove that these medications directly damage hair follicles.

That distinction matters. It keeps a concerning change from turning into a frightening conclusion, and it points toward a more useful next step: document what is happening, bring it to your medical team, and care for your scalp and hair gently while the cause is evaluated.

**This article is educational and is not medical advice. Do not stop or change a prescription medication without speaking with the clinician who prescribed it.

What the current evidence actually says

Hair loss appears in the current FDA prescribing information for both Wegovy (semaglutide) and Zepbound (tirzepatide). In adult weight-reduction trials for Wegovy, hair loss was reported by 3% of participants receiving the medication and 1% receiving placebo. In pooled adult weight-reduction trials for Zepbound, the figures were 4% to 5% across treatment doses and 1% with placebo [1,2].

Those numbers establish that hair loss was reported during the trials. They do not establish the cause of each case.

A 2026 meta-analysis combined nine interventional studies with 4,114 GLP-1 users. The pooled relative risk was 3.25 compared with placebo, while the single-arm event rate among GLP-1 users was 3.9% [3]. The relative increase sounds large, but the absolute event rate helps put it in context. The confidence interval around the risk estimate was also wide, and the analysis could not tell whether the medication, weight loss, nutrition, or another factor explained an individual case.

A separate 2026 systematic review reached a similarly careful conclusion. Across 24 studies, reports were more frequent with semaglutide and tirzepatide than with other agents. Telogen effluvium and androgenetic alopecia were the most commonly described patterns when a subtype was recorded, but many reports did not classify the hair change at all. The authors called for prospective studies to clarify timing, cause, and who may be most susceptible [4].

The signal is credible, but its mechanism remains unsettled.

Why shedding may begin months after weight loss starts

One plausible explanation is telogen effluvium, a form of excessive shedding that can follow a physical or emotional stressor. Significant weight loss is one recognized trigger. Instead of falling immediately, more hairs shift into a resting phase and shed later, which is why the timing can feel confusing.

The American Academy of Dermatology notes that people often notice excessive shedding a few months after the triggering event. When the body readjusts and the trigger resolves, fullness often returns over time, although the course varies and some people have more than one type of hair loss at once [5].

Reduced food intake may matter too. A 2026 narrative review found possible nutritional shortfalls among GLP-1 users, but most of its evidence came from observational data and could not prove that the medication caused those deficiencies [6]. Protein, iron, zinc, vitamin D, thyroid function, hormonal changes, illness, and other factors can all enter a clinician's evaluation. Guessing from symptoms alone is unreliable.

What to do if you notice more shedding: Record the pattern, not every strand

Take a photo of your part and hairline once a month in the same lighting and from the same angle. Note when you started the medication, dose changes, major weight changes, illness, surgery, high stress, or a change in diet. A simple timeline is more useful at an appointment than trying to count every hair in the drain.

Bring both your prescriber and a dermatologist into the conversation

Tell your prescriber what you are seeing rather than changing the dose or stopping treatment on your own. A board-certified dermatologist can examine the scalp, distinguish shedding from breakage or patterned thinning, and decide whether testing is appropriate.

Seek medical evaluation promptly for sudden or patchy loss, a painful or inflamed scalp, spreading scale, broken skin, or much more shedding than usual. Mayo Clinic specifically advises medical review for sudden or patchy hair loss or a noticeable increase during combing or washing [7].

Review nutrition without reaching for megadoses

If appetite has changed substantially, ask your clinician or a registered dietitian whether you are meeting your needs for total energy and protein, and whether laboratory testing makes sense. Do not assume that a high-dose "hair vitamin" is harmless. The American Academy of Dermatology advises checking for deficiency before supplementing; excessive amounts of some nutrients can make hair loss worse or create other health risks [8].

Make hair care quieter

When hair feels fragile, reduce avoidable breakage. Apply shampoo mainly to the scalp, condition after washing, detangle gently, loosen tight styles, and turn down the heat on dryers and styling tools. These steps do not treat telogen effluvium or another medical cause. They simply keep mechanical damage from adding more noise to an already stressful situation [9].

Where scalp care fits

A clean, comfortable scalp routine can support hair wellness while you and your medical team address the bigger picture. Keep the routine simple enough to follow. If the scalp is inflamed, painful, or broken, pause new cosmetic products until a clinician advises you.

KeraFactor publishes this article and makes the product discussed here. KeraFactor Scalp Stimulating Solution is a daily cosmetic scalp-care product. According to its current product page, it is drug-free and hormone-free and is formulated to nourish the scalp while supporting visibly thicker, fuller, and stronger-looking hair [10]. It does not diagnose, prevent, treat, or reverse GLP-1-associated hair loss or telogen effluvium. Use it only as directed, and ask your clinician how a cosmetic scalp product fits alongside any medical plan.

Explore KeraFactor Scalp Stimulating Solution: https://shop.mykerafactor.com/products/kerafactor-scalp-stimulating-solution

The useful takeaway

Hair shedding during GLP-1 treatment is a real reported concern, but it is not a one-cause story. The medication, the pace of weight loss, changing nutrition, a separate hair condition, or several factors at once may be involved.

Use the evidence as a reason to check in with your medical team, not as a reason to change a prescription after reading a social post. Build a timeline, get the pattern evaluated, protect fragile hair, and keep cosmetic scalp care in its proper supporting role.

Source notes

Research query: GLP-1 receptor agonists, semaglutide, tirzepatide, hair loss, telogen effluvium, nutrition, and consumer hair-care guidance. Sources accessed August 1, 2026.

1. U.S. Food and Drug Administration. [Wegovy prescribing information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf), 2025. Adult weight-reduction adverse-reaction table: hair loss 3% with Wegovy 2.4 mg and 1% with placebo. A separate pediatric table reports different figures and was not used in the article.
2. U.S. Food and Drug Administration. [Zepbound prescribing information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf), 2026. Pooled adult weight-reduction trials: hair loss 4% to 5% across treatment doses and 1% with placebo.
3. Cheng PL, Chang HC. [Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/42155605/). *Diabetes Research and Clinical Practice*. 2026;237:113333. PMID: 42155605.
4. Gupta AK, Teasell EM, Economopoulos V, Mirmirani P. [GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling](https://pubmed.ncbi.nlm.nih.gov/41998799/). *Science Progress*. 2026;109(2). PMID: 41998799.
5. American Academy of Dermatology. [Do you have hair loss or hair shedding?](https://www.aad.org/public/diseases/hair-loss/insider/shedding).
6. [Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy: A Narrative Review](https://pubmed.ncbi.nlm.nih.gov/41549912/). 2026. PMID: 41549912. Observational-data limitations noted in the article.
7. Mayo Clinic. [Hair loss: Symptoms and causes](https://www.mayoclinic.org/diseases-conditions/hair-loss/symptoms-causes/syc-20372926). Updated February 7, 2026.
8. American Academy of Dermatology. [Hair loss: Tips for managing](https://www.aad.org/public/diseases/hair-loss/treatment/tips).
9. American Academy of Dermatology. [Tips for healthy hair](https://www.aad.org/public/everyday-care/hair-scalp-care/hair/healthy-hair-tips). Updated August 12, 2024.
10. KeraFactor. [Scalp Stimulating Solution](https://shop.mykerafactor.com/products/kerafactor-scalp-stimulating-solution). Current live product page accessed August 1, 2026.
11. American Academy of Dermatology. [How can GLP-1 drugs affect my skin, hair, and nails?](https://www.aad.org/public/everyday-care/skin-care-secrets/prevent-skin-problems/glp1-drugs-and-side-effects). Updated February 17, 2026.
12. Piraccini BM, Vano-Galvan S, Blume-Peytavi U, Ribet V, Mengeaud V. [Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes](https://pubmed.ncbi.nlm.nih.gov/42249225/). *Dermatology and Therapy*. 2026;16(7):3345-3360. PMID: 42249225.